32
Participants
Start Date
July 31, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Single dose C2N-8E12
C2N-8E12 is a humanized recombinant anti-human tau antibody.
Single dose placebo
Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
Mayo Clinic, Jacksonville
University of Florida College of Medicine, Gainesville
University of Alabama, Birmingham
Indiana University Medical Center, Indianapolis
Mayo Clinic, Rochester
Texas Health Presbyterian Dallas, Dallas
Mayo Clinic, Scottsdale
University of California, Los Angeles (UCLA), Los Angeles
UCSD Department of Neurosciences, San Diego
University of California, San Francisco, San Francisco
Columbia University, New York
Vanderbilt University Medical Center, Nashville
Lead Sponsor
C2N Diagnostics
INDUSTRY